Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.

Clinical trial details

A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors

Identifier

MS202329_0001

Sponsor

MERCK HEALTHCARE KGAA

Principal Investigator

ELENA GARRALDA CABANAS

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : ADC
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: M9140

Links

Clinical Trials GOV (NCT identifier): NCT05464030
EU Clinical Trials Register (eudraCT Identifier): 2022-500508-23